AMICUS THERAPEUTICS INC. - COMMON STOCK

Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2023

01 Sep 2023 07:00:18 By Nasdaq GlobeNewswire

Amicus Therapeutics Announces Presentation and Posters at the SSIEM Annual Symposium 2023

29 Aug 2023 07:00:00 By Nasdaq GlobeNewswire

Amicus Therapeutics Appoints Simon Harford as Chief Financial Officer

21 Aug 2023 07:00:00 By Nasdaq GlobeNewswire

Amicus Therapeutics Announces Approval and Launch of New Pompe Disease Therapy in the United Kingdom

15 Aug 2023 07:00:00 By Nasdaq GlobeNewswire

NetDania - New 12 months High: AMICUS THERAPEUTICS INC. - COMMON STOCK

09 Aug 2023 09:45:02 By NetDania Notify

NetDania - New 12 months High: AMICUS THERAPEUTICS INC. - COMMON STOCK

08 Aug 2023 16:15:05 By NetDania Notify

Amicus Therapeutics Announces Second Quarter 2023 Financial Results and Corporate Updates

08 Aug 2023 07:00:01 By Nasdaq GlobeNewswire

Amicus Therapeutics to Announce Second Quarter 2023 Financial Results on August 8, 2023

31 Jul 2023 07:00:00 By Nasdaq GlobeNewswire

NetDania - New 12 months High: AMICUS THERAPEUTICS INC. - COMMON STOCK

21 Jul 2023 09:48:54 By NetDania Notify

Amicus Therapeutics Announces Approval and Launch of New Pompe Disease Therapy in the European Union

27 Jun 2023 07:00:00 By Nasdaq GlobeNewswire

Amicus Therapeutics Announces First Quarter 2023 Financial Results and Corporate Updates

10 May 2023 07:00:02 By Nasdaq GlobeNewswire

Amicus Therapeutics to Present at the Bank of America 2023 Health Care Conference

02 May 2023 07:00:01 By Nasdaq GlobeNewswire

Amicus Therapeutics to Announce First Quarter 2023 Financial Results on May 10, 2023

01 May 2023 07:00:01 By Nasdaq GlobeNewswire

Amicus Therapeutics Receives Positive CHMP Opinion for Opfolda® (miglustat) for Late-Onset Pompe Disease

26 Apr 2023 13:00:33 By Nasdaq GlobeNewswire

Amicus Therapeutics Announces European Commission Approval for Pombiliti™ in Patients with Late-Onset Pompe Disease

27 Mar 2023 07:00:09 By Nasdaq GlobeNewswire

Amicus Therapeutics Announces Full-Year 2022 Financial Results and Corporate Updates

01 Mar 2023 07:00:02 By Nasdaq GlobeNewswire

Amicus Therapeutics to Present at the Cowen 43rd Annual Health Care Conference

27 Feb 2023 07:00:00 By Nasdaq GlobeNewswire

Amicus Therapeutics Announces Positive Long-Term Data from Phase 3 Open-label Extension Study of AT-GAA in Late-Onset Pompe Disease at the 19th Annual WORLDSymposium™ 2023

22 Feb 2023 17:00:08 By Nasdaq GlobeNewswire

Amicus Therapeutics to Announce Full-Year 2022 Financial Results on March 1, 2023

14 Feb 2023 07:00:00 By Nasdaq GlobeNewswire

Amicus Therapeutics Announces Presentations and Posters at the 19th Annual WORLDSymposium™ 2023

13 Feb 2023 07:00:00 By Nasdaq GlobeNewswire